The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 301–400 of 1,006
Yu, J., Wu, X., Yan, J., Yu, H., Xu, L., Chi, Z., Sheng, X., Si, L., Cui, C., Dai, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0548-2 · Cited by 191
Stenger, D., Stief, T. A., Kaeuferle, T., Willier, S. M., Rataj, F., Schober, K., Vick, B., Lotfi, R., Wagner, B., Grünewald, T. G. P., et al. (2020) · Blood · doi:10.1182/blood.2020005185 · Cited by 196
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Ramakrishna, S., Highfill, S. L., Walsh, Z. H., Nguyen, S. M., Lei, H., Shern, J. F., Qin, H., Kraft, I. L., Stetler‐Stevenson, M., Yuan, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3784 · Cited by 188
Self-citationCAR T Cell Therapy: A Game Changer in Cancer Treatment
Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016) · Journal of Immunology Research · doi:10.1155/2016/5474602 · Cited by 186
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martinez-Paniagua, M. A., Sanber, K. S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0792-2 · Cited by 189
Lickefett, B., Chu, L., Ortiz‐Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D. A., Hudecek, M., Kremer, A., Markman, J. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 200
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Zammarchi, F., Corbett, S., Adams, L. R., Tyrer, P. C., Kiakos, K., Janghra, N., Marafioti, T., Britten, C. E., Havenith, C. E. G., Chivers, S., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813493 · Cited by 181
CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
Li, J., Piskol, R., Ybarra, R., Chen, Y.-J. J., Li, J., Slaga, D., Hristopoulos, M. L., Clark, R., Modrusan, Z. D., Tótpál, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8861 · Cited by 184
Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182
Mata, M., Gerken, C. P., Nguyen, P., Krenciute, G., Spencer, D. M., & Gottschalk, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0263 · Cited by 181
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 182
Cytokine Release Syndrome: Current Perspectives
Murthy, H. S., Iqbal, M., Chávez, J. C., & Kharfan‐Dabaja, M. A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s202015 · Cited by 188
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 197
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Self-citationNew cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Hay, K. A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15644 · Cited by 177
Current Progress in CAR-T Cell Therapy for Hematological Malignancies
Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2020) · Journal of Cancer · doi:10.7150/jca.48976 · Cited by 184
Hu, Y., Sun, J., Wu, Z., Yu, J., Cui, Q., Pu, C., Liang, B., Luo, Y., Shi, J., Jin, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0299-5 · Cited by 180
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lee, L. S. H., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas‐Filipowicz, D., Onuoha, S. C., Thomas, S., Baldan, V., Bughda, R., et al. (2017) · Blood · doi:10.1182/blood-2017-05-781351 · Cited by 180
Chimeric antigen receptor signaling: Functional consequences and design implications
Lindner, S. E., Johnson, S. M., Brown, C. E., & Wang, L. D. (2020) · Science Advances · doi:10.1126/sciadv.aaz3223 · Cited by 178
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D’Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 184
Future perspectives in melanoma research
Ascierto, P. A., Agarwala, S. S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 176
Self-citationAutologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
Kooreman, N. G., Kim, Y., de Almeida, P. E., Termglinchan, V., Diecke, S., Shao, N., Wei, T.-T., Yi, H., Dey, D., Nelakanti, R. V., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.016 · Cited by 173
Cao, J., Wang, G., Cheng, H., Wei, C., Qi, K., Sang, W., Li, Z., Shi, M., Li, H., Qiao, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25108 · Cited by 176
Hegde, M. G., Joseph, S. K., Pashankar, F., DeRenzo, C. C., Sanber, K. S., Navai, S. A., Byrd, T. T., Hicks, J. M., Xu, M. L., Gerken, C. P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17175-8 · Cited by 175
Self-citationChimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 178
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, M.-E., & Bargou, R. C. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1161185 · Cited by 178
Lamers, C. H. J., Klaver, Y., Gratama, J. W., Sleijfer, S., & Debets, R. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160037 · Cited by 170
Shalabi, H., Kraft, I. L., Wang, H., Yuan, C. M., Yates, B., Delbrook, C., Zimbelman, J. D., Giller, R., Stetler‐Stevenson, M., Jaffe, E. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183459 · Cited by 170
Self-citationSiriwon, N., Kim, K. G., Siegler, E. L., Chen, X., Rohrs, J. A., Liu, Y., & Wang, P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0502 · Cited by 173
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Sato, Y., Bando, H., Piazza, M., Gowing, G., Herberts, C. A., Jackman, S. M., Leoni, G., Libertini, S., MacLachlan, T. K., McBlane, J. W., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.10.001 · Cited by 172
Tasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O. E., Kozlowski, M. S., Li, Y., Schrank-Hacker, A. M., Morrissette, J. J. D., Carroll, M. P., et al. (2017) · Blood · doi:10.1182/blood-2016-08-736041 · Cited by 172
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh, M., Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 189
Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 168
Ortiz‐Maldonado, V., Rives, S., Castellà, M., Alonso‐Saladrigues, A., Benítez‐Ribas, D., Caballero‐Baños, M., Baumann, T., Cid, J., García‐Rey, E., Llanos, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.027 · Cited by 176
Heitzeneder, S., Bosse, K. R., Zhu, Z., Zhelev, D. V., Majzner, R. G., Radosevich, M., Dhingra, S., Sotillo, E., Buongervino, S. N., Pascual‐Pasto, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.005 · Cited by 174
Self-citationRosenblatt, J. M., Stone, R. M., Uhl, L., Neuberg, D. S., Joyce, R., Levine, J. D., Arnason, J. E., McMasters, M., Luptakova, K., Jain, S. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 168
Genetically modified T cells in cancer therapy: opportunities and challenges
Sharpe, M. E., & Mount, N. M. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018036 · Cited by 172
Tashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B. A., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 162
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M. A., Ahlman, M. A., Stetler‐Stevenson, M., Yuan, C. M., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 162
Self-citationShalabi, H., Qin, H., Su, A. H., Yates, B., Wolters, P. L., Steinberg, S. M., Ligon, J. A., Silbert, S. K., DéDé, K., Benzaoui, M., et al. (2022) · Blood · doi:10.1182/blood.2022015795 · Cited by 166
Self-citationSequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Pan, J., Zuo, S., Deng, B., Xu, X., Li, C., Zheng, Q., Ling, Z., Song, W., Xu, J., Duan, J., et al. (2019) · Blood · doi:10.1182/blood.2019003293 · Cited by 164
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 166
Dourthe, M.-É., Rabian, F., Yakouben, K., Chevillon, F., Cabannes‐Hamy, A., Mechinaud, F. M., Grain, A., Chaillou, D., Rahal, I., Caillat‐Zucman, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01281-7 · Cited by 164
Immunotherapy for Brain Tumors
Sampson, J. H., Maus, M. V., & June, C. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8089 · Cited by 156
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Felsenstein, K. M., & Theodorescu, D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.179 · Cited by 159
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Autologous lymphapheresis for the production of chimeric antigen receptor T cells
Allen, E. S., Stroncek, D. F., Ren, J., Eder, A. F., West, K. A., Fry, T. J., Lee, D. W., Mackall, C. L., & Conry‐Cantilena, C. (2017) · Transfusion · doi:10.1111/trf.14003 · Cited by 161
Self-citationChimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Subklewe, M. S., von Bergwelt‐Baildon, M., & Humpe, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000496870 · Cited by 161
Current challenges and emerging opportunities of CAR-T cell therapies
Abreu, T. R., Fonseca, N. A., Gonçalves, N., & Moreira, J. N. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.047 · Cited by 159
A new era of cancer phototherapy: mechanisms and applications
Wang, Y., Ma, K., Kang, M., Yan, D., Niu, N., Yan, S., Sun, P., Zhang, L., Sun, L., Wang, D., et al. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00708e · Cited by 162
Self-citationT cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Self-citationImmunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Sun, S., He, H., Yang, G., Zhang, Y., & Fu, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/2386187 · Cited by 163
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Sheykhhasan, M., Manoochehri, H., & Dama, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00418-1 · Cited by 165
Enhanced T cell effector activity by targeting the Mediator kinase module
Freitas, K. A., Belk, J. A., Sotillo, E., Quinn, P. J., Ramello, M. C., Malipatlolla, M. B., Dániel, B., Sándor, K., Klysz, D. D., Bjelajac, J. R., et al. (2022) · Science · doi:10.1126/science.abn5647 · Cited by 159
Self-citationTang, X., Sun, X., Huang, K.-M., Zhang, L., Yang, Z., Zou, D., Wang, B., Warnock, G. L., Dai, L., & Luo, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6175 · Cited by 159
Self-citation4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 163
Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., Kaiser, A. D., Assenmacher, M., Döring, M., Feucht, J., & Feuchtinger, T. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2155-7 · Cited by 155
Rafiq, S., Purdon, T. J., Daniyan, A. F., Koneru, M., Dao, T., Liu, C., Scheinberg, D. A., & Brentjens, R. J. (2016) · Leukemia · doi:10.1038/leu.2016.373 · Cited by 157
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 159
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Guedan, S., & Alemany, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02460 · Cited by 158
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
Arcangeli, S., Rotiroti, M. C., Bardelli, M., Simonelli, L., Magnani, C. F., Biondi, A., Biagi, E., Tettamanti, S., & Varani, L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.017 · Cited by 152
Biasco, L., Izotova, N., Rivat, C., Ghorashian, S., Richardson, R., Guvenel, A., Hough, R. E., Wynn, R. F., Popova, B., Lopes, A., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00207-7 · Cited by 155
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Gomes‐Silva, D., Atilla, E., Atilla, P. A., Mo, F., Tashiro, H., Srinivasan, M., Lulla, P., Rouce, R. H., Cabral, J. M. S., Ramos, C. A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.001 · Cited by 155
Brændstrup, P., Levine, B. L., & Ruella, M. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2019.12.004 · Cited by 163
Castella, M., Caballero-Baños, M., Ortiz-Maldonado, V., González-Navarro, E. A., Suñé, G., Antoñana-Vidósola, A., Boronat, A., Marzal, B., Millán, L., Martín-Antonio, B., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00482 · Cited by 150
Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L. M., Steimle, B. L., Mahmud, H., Anthony-Gonda, K., Krueger, W. H., Zhu, Z., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6401 · Cited by 152
Self-citationMartínez-Vélez, N., García-Moure, M., Marigil, M., González-Huarriz, M., Puigdelloses, M., Pérez‐Larraya, J. G., Zalacaín, M., Marrodán, L., Varela-Guruceaga, M., Laspidea, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10043-0 · Cited by 149
Exhaustion of CAR T cells: potential causes and solutions
Kouro, T., Himuro, H., & Sasada, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03442-3 · Cited by 156
Stroncek, D. F., Ren, J., Lee, D. W., Tran, M., Frodigh, S. E., Sabatino, M., Khuu, H., Merchant, M. S., & Mackall, C. L. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.04.003 · Cited by 148
Self-citationZhou, J., Jin, L., Wang, F., Zhang, Y., Liu, B., & Zhao, T. (2019) · Protein & Cell · doi:10.1007/s13238-019-0643-y · Cited by 151
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 151
Self-citationIn vivo imaging of nanoparticle-labeled CAR T cells
Kiru, L., Zlitni, A., Tousley, A. M., Dalton, G. N., Wu, W. E., Lafortune, F., Liu, A., Cunanan, K. M., Nejadnik, H., Sulchek, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102363119 · Cited by 152
Benjamin, R., Jain, N., Maus, M. V., Boissel, N., Graham, C., Jóźwik, A., Yallop, D., Konopleva, M. Y., Frigault, M. J., Teshima, T., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00245-9 · Cited by 158
Metabolic challenges and interventions in CAR T cell therapy
Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 156
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
Gökbuget, N., Boissel, N., Chiaretti, S., Dombret, H., Doubek, M., Fielding, A. K., Foà, R., Giebel, S., Hoelzer, D. F., Hunault, M., et al. (2024) · Blood · doi:10.1182/blood.2023023568 · Cited by 158
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 168
Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 149
Haydar, D., Houke, H., Chiang, J., Yi, Z., Odé, Z., Caldwell, K. J., Zhu, X., Mercer, K., Stripay, J. L., Shaw, T. I., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa278 · Cited by 144
Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadiñanos-Garai, A., Vispute, K., Bosshard‐Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00917 · Cited by 151
Jiang, H., Li, C., Yin, P., Guo, T., Liu, L., Xia, L., Wu, Y., Zhou, F., Ai, L., Shi, W., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25582 · Cited by 148
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 146
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 148
Hay, K. A., & Turtle, C. J. (2017) · Drugs · doi:10.1007/s40265-017-0690-8 · Cited by 144
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
Self-citationRiegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 148
Self-citationBrüggemann, M., & Kotrová, M. (2017) · Hematology · doi:10.1182/asheducation-2017.1.13 · Cited by 140
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 142
Self-citationToxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 144
Nellan, A., Rota, C., Majzner, R. G., McCully, C. L., Griesinger, A. M., Levy, J. M. M., Foreman, N. K., Warren, K. E., & Lee, D. W. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0340-z · Cited by 145
Self-citationCo-Stimulatory Receptor Signaling in CAR-T Cells
Honikel, M. M., & Olejniczak, S. H. (2022) · Biomolecules · doi:10.3390/biom12091303 · Cited by 149
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
